Text Size

Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2005 by Royal Brompton & Harefield NHS Foundation Trust.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
CORDA, The Heart Charity
The Cooley’s Anemia Foundation,
Apotex Inc.
The UK Thalassemia Society
Information provided by:
Royal Brompton & Harefield NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT00103753
First received: February 14, 2005
Last updated: June 23, 2005
Last verified: February 2005
History of Changes
  Purpose

Thalassemia major is a genetic disorder affecting hemoglobin synthesis, rendering individuals dependent upon lifelong blood transfusions. Consequently, iron overload occurs and patients have shortened life expectancy with the most common cause of death being heart failure. This trial tests whether the combination of traditional therapy (deferoxamine) with a newer drug (deferiprone) will prove more effective in removing cardiac iron than deferoxamine alone.


Condition Intervention Phase
Beta-Thalassemia
 Drug: deferiprone
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance

Resource links provided by NLM:

MedlinePlus related topics: Iron Thalassemia
U.S. FDA Resources

Further study details as provided by Royal Brompton & Harefield NHS Foundation Trust:

Primary Outcome Measures:
  • Myocardial T2*

Secondary Outcome Measures:
  • Liver T2*
  • LV and RV volumes and function in systole and diastole
  • Brachial artery reactivity
  • B-type natriuretic peptide
  • Patient compliance
  • Adverse events
  • Success of blinding

Estimated Enrollment: 65
Study Start Date: May 2004
Estimated Study Completion Date: June 2005
Detailed Description:

Thalassemia Major (TM) is a hereditary anemia resulting from a single gene defect that results in abnormal red cell production. The survival of affected individuals is dependent upon lifelong blood transfusions. Unfortunately, this causes total body iron overload, and 50% of the patients in the UK are dead by the age of 35. Approximately 70% of these deaths result from heart failure which results as a consequence of cardiac iron toxicity.

A Cardiovascular Magnetic Resonance (CMR) technique (which exploits the fact that T2* signal decay relates to tissue iron) developed at the Royal Brompton Hospital provides a non-invasive and reproducible assessment of cardiac iron. CMR therefore provides a very useful method to assess response to new treatments in this condition. Using cardiac T2* as a primary endpoint, we will investigate whether the oral chelator, deferiprone in combination with traditional treatment (deferoxamine), is superior in removing cardiac iron as compared to deferoxamine alone. This trial will provide the first randomized controlled, double-blinded, evidence for the efficacy of combination treatment in TM.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Beta thalassemia major
  • Maintaining pre-transfusion hemoglobin of 9 g/dL
  • Myocardial T2* between 8 and 20 ms
  • Ability to give informed consent
  • Male or female
  • Age >18 years
  • Any ejection fraction
  • Confirmation of effective contraception throughout the trial (both men and women)

Exclusion Criteria:

  • Implant incompatible with MR (magnetic resonance), such as pacemaker, claustrophobia, or other condition making CMR impossible or inadvisable
  • Neutropenia within 12 months (ANC <1.5 x10^9/L), unless normal at screening
  • Thrombocytopenia within 12 months (<50 x10^9/L), unless normal at screening
  • Liver enzymes > 3 times upper limit of normal
  • Patients who have previously received deferiprone for a total of more than 6 months over the last 5 years.
  • Patients with a previous reaction to deferiprone
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00103753

Locations
Italy
Ospedale Microcitemico, Via Jenner
Cagliari, Sardinia, Italy, 09121
Sponsors and Collaborators
Royal Brompton & Harefield NHS Foundation Trust
CORDA, The Heart Charity
The Cooley’s Anemia Foundation,
Apotex Inc.
The UK Thalassemia Society
  More Information

No publications provided by Royal Brompton & Harefield NHS Foundation Trust

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00103753     History of Changes
Other Study ID Numbers: 02 065
Study First Received: February 14, 2005
Last Updated: June 23, 2005
Health Authority: United Kingdom: National Health Service

Keywords provided by Royal Brompton & Harefield NHS Foundation Trust:
Randomized Controlled Trial
Deferiprone
Deferoxamine
Iron chelation
Beta Thalassemia Major

Additional relevant MeSH terms:
Beta-Thalassemia
Thalassemia
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn
 Deferoxamine
Deferiprone
Siderophores
Iron Chelating Agents
Chelating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 21, 2013